MCM
DMRA

MAI Capital Management’s Damora Therapeutics DMRA Stock Holding History

MAI Capital Management’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-9,811
Closed -$618K – 1090
2023
Q2 		$618K Sell
9,811
-407
-4% -$22.2K 0.01% 552
2023
Q1 		$508K Buy
10,218
+887
+10% +$46.8K 0.01% 635
2022
Q4 		$268K Sell
9,331
-4,226
-31% -$175K ﹤0.01% 805
2022
Q3 		$641K Buy
13,557
+723
+6% +$36.7K 0.01% 484
2022
Q2 		$555K Buy
+12,834
New +$589K 0.01% 520

Other funds holding DMRA

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MAI Capital Management's DMRA Position: Q3 2023 in Review

MAI Capital Management sold out of Damora Therapeutics (DMRA) in Q3 2023, closing a stake of 9,811 shares — an estimated $618K sold.

MAI Capital Management first reported a position in DMRA in Q2 2022 and held it in 5 quarters. The position peaked at $641K in Q3 2022. 21 funds tracked by Wall St. Rank hold DMRA as of Q3 2023.

  • MAI Capital Management reported no remaining Damora Therapeutics position as of Q3 2023 after selling out during the quarter.
  • MAI Capital Management sold 9,811 Damora Therapeutics shares in Q3 2023, an estimated $618K.
  • MAI Capital Management first reported a position in Damora Therapeutics in Q2 2022 and held it in 5 quarters.
  • MAI Capital Management's Damora Therapeutics position peaked at $641K in Q3 2022.
  • 21 funds tracked by Wall St. Rank held Damora Therapeutics as of Q3 2023.

Based on MAI Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.